Slippery Slope: The Master of the Game

Sales of new anticoagulant drugs are booming, thanks to their convenience -- but thanks also to new guidelines that endorse their use and new risk scale that greatly expands the pool of potential patients.

At the center of both guidelines and risk assessment is Gregory Lip, MD, a British heart doctor with extensive financial ties to the pharmaceutical industry.

For years, Lip has worked as a paid speaker and consultant to companies that make novel (or newer) anticoagulants (NOACs), which are marketed for prevention of stroke in patients with atrial fibrillation as well as for prevention of deep vein thrombosis (DVT).

Inflating the Need?

According to a recent estimate, as many 5.2 million people in the U.S. have atrial fibrillation.

The new drugs were approved by the U.S. Food and Drug Administration beginning in 2010 as alternatives to warfarin, which was approved in 1954. They are billed as more...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.medpagetoday.com/special-reports/slipperyslope/52875